cyrilzakka/clinical-trials huggingface dataset:
Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms

The purpose of the bCAN study is to create a prospective collection of multimodal data and human samples, linked to the French Intracranial Aneurysm Registry (FRAN).

The aim of bCAN is to enable risk stratification of ruptured ICAs by redefining "intracranial aneurysm disease". The description of genotypically and phenotypically specific subgroups of cases will pave the way for improved patient management based on new diagnostic/prognostic strategies among AIC carriers, either in a familial context, or at the level of the general population.

The main objective of bCAN study is to build a predictive model of intracranial aneurysm phenotypes through the combination of information on genetic mutations, imaging findings and ICA rupture characteristics.

The secondary objectives of the bCAN study are (i) to study morphological characterization of ICA and vascular bifurcations, (ii) to deepen knowledge of genotype/clinical and biological phenotype relationships according to the genes identified in the different families, (iii) to research and validate the relationships between genotypes and phenotypes (including rupture) of ICA in a large population of sporadic ICA cases.

Eligibility Criteria:
Inclusion criteria for sporadic ICA cases:

* Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and/or cerebral arteriography
* Aneurysm discovered less than a year ago, with initial imaging (MRI and/or CTA and DSA) available
* Written consent obtained for study participation
* Patient covered by a social security plan

Inclusion criteria for index and related cases (familial forms) of intracranial aneurysms (ICA):

* Index case: Any adult patient consulting for a definite and typical bifurcation ICA presenting at least one other case with ICA related to the 1st or 2nd degree (child, parent, brother, sister) detected by MRI with at least one Time of Flight (TOF) sequence.
* Family relatives: All 1st- and 2nd-degree relatives (children, parents, brothers, sisters), of legal age, of patients with a family history of definite, typical bifurcation AIC (≥ 2 affected), Screening to be performed using MRI with at least a Time of Flight (TOF) sequence.
* Written consent to participate in the study
* Patient and relatives covered by a social security plan

Exclusion Criteria:

* Syndromic diagnosis known to cause ICA: Marfan syndrome, OSA with SMAD 3, Elhers Danlos syndrome type II and IV, Autosomal Dominant Cystic Fibrosis, Moya-Moya syndrome
* AIC with : Dissecting or fusiform, Associated with arteriovenous malformation, Blister-like, Mycotic
* Cerebral white matter pathology detected on MRI evoking : Col4a1 mutation
* Patient under guardianship or conservatorship
* Person under court protection
* Contraindication to an MRI scan
Biologic Assessment of Satiety

Subjective measures of satiety are correlated with biologic mechanisms of appetite control.


Eligibility Criteria:
Inclusion Criteria:

* medical history (interview) demonstrating good health
* non-smoking
* not taking steroid-based medications
* not planning to or currently attempting to gain or lose weight
* being willing to consent to study conditions
* healthy adults ages 25-45 years
* body mass index between 18-30 kg/m2.
* University of North Dakota students may participate but student status is not required.

Exclusion Criteria:

* diagnosed eating disorders
* current or planned pregnancy
* lactation
* unmanaged hypertension (systolic \>160 mmHg or diastolic \> 100mmHg) and/or other cardiovascular, pulmonary, skeletal and metabolic diseases
* taking medications known to affect appetite, body composition, weight, or food intake
Effect of Coherent Breathing on Elderly Quality of Life

This study will be carried out on sixty elderlies of both gender with ages ranges from 60 to 70 years old. The participants will receive Inspiratory muscle trainer and/or Coherent breathing exercise three times per week for 12 weeks.


Eligibility Criteria:
Inclusion Criteria:

1. Elderly subject of both gender with age ranged from 60 to 70 years old.
2. BMI will be ranged from 25 to 29.9.
3. Clinically and medically stable.
4. Able to understand the requirements of the study.
5. Conscious patient and respond to verbal command.

Exclusion Criteria:

1. Neurological conditions (e.g., stroke history, Parkinson's disease).
2. Presence of an acute illness.
3. Metabolically unstable chronic illness.
4. Pre-existent untreated metabolic or renal disease.
5. Patient undergoes chemotherapy.
6. Recent surgery.
7. Uncontrolled diabetes or hypertension.
Postoperative Pain Management on Uvulopalatopharyngoplasty Patients

This is a randomized controlled study, aimed to investigate the effects of dinalbuphine sebacate (DS) on patients having uvulopalatopharyngoplasty (UPPP). DS is a prodrug of nalbuphine, a mixed agonist-antagonist opioid. The mean absorption time for the complete release of DS into systemic circulation is approximately 145 h, which could theoretically provide extended analgesic effects for up to 6 days. Patients diagnosed with obstructive sleep apnea are generally associated with higher risks towards opioid side effects, especially respiratory depression. Post-UPPP pain managing should be cautiously arranged and executed. We hypothesize that the combination of our routine practice and DS will improve the outcomes after Uppp.

Within 4 weeks before uvulopalatopharyngoplasty, patients are invited for this study. After written informed consent gained, the eligibilities are checked. Eligible patients are arrogated into experimental or control group randomly prior to surgery. Experimental group receives the DS administration at least 12 hours before surgery. During peri-operative period, pain management are conducted following our routine practice. Pain intensity, consumption of analgesics, adverse events, swallow function and life quality are all assessed and recorded within 14 days after surgery.

Eligibility Criteria:
Inclusion Criteria:

* aged between 20 and 65.
* diagnosed with obstructive sleep apnea.
* arranged to undergo uvulopalatopharyngoplasty.
* classified as ASA I, II, or III.

Exclusion Criteria:

* can not comply with study protocol.
* BMI \> 34 kg/m2.
* history of chronic pain.
* history of narcotics or alcohol abuse.
* allergic to NSAID.
* diagnosed as diabetes mellitus with poor glycemic control.
* diagnosed with severe cardiovascular or respiratory diseases.
* judged as an unsuitable subject by investigators.
Intravascular Ultrasound-derived Assessment of Hemodynamically Negative Lesions in NSTEACS Patients

This is an observational and prospective cohort study to examine whether the addition of IVUS plaque morphological evaluation to FFR haemodynamic assessment of non-culprit lesions in NSTEACS patients will better predict MACEs.

IMPACT-NSTEACS is a prospective, single-centre and dynamic observational study. The study population consists of NSTEACS patients who undergo FFR in lesions with intermediate to severe angiographic stenosis. Then, FFR-guided PCI is performed, followed by morphological assessment based on IVUS in all FFR-negative lesions (FNLs). After discharge all patients receive optimal medication treatment and are followed up clinically. On the basis of follow-up angiography, MACEs are further adjudicated as occurring at FNLs or not.

Eligibility Criteria:
Clinical Inclusion Criteria:

1. Moderate to high risk NSTEACS requiring invasive strategy based on current guidelines and local clinical practice.
2. Patient agrees and is able to follow all protocol procedures.

Clinical Exclusion Criteria:

1. STEMI or SCAD.
2. Hemodynamic instability (e.g. cardiogenic shock, refractory ventricular arrhythmias, acute and severe conduction system disease and left ventricular ejection fraction ≤30%).
3. Contraindication for FFR, PCI, IVUS and OMT (e.g. severe allergy to antiplatelet drug or contrast, significant bleed within the past 6 months, bleeding diathesis and serum creatinine ≥2.5 mg/dl).
4. PCI within 6 months or any prior CABG.
5. Anticipated life expectancy \<3 year.
6. Pregnancy
7. Unwilling or unable to provide informed consent

Imaging Inclusion Criteria

1. Patients must have at least \> 1 de novo lesion in a native coronary segment with a visually estimated diameter stenosis of between 40 and 90 %.
2. Successful FFR-guided PCI performed in all major epicardial coronary arteries (including their branches): PCI for all lesions a) with 40%-90% diameter stenosis and FFR\<0.8 and b) with ≥90% diameter stenosis.
3. The FFR-negative lesions must be available for assessment of IVUS.

Imaging Exclusion Criteria:

1. Target lesion reference diameter \<2.0 mm.
2. Anatomic conditions precluding FFR and IVUS (e.g. marked calcification or tortuosity, chronic total occlusion or thrombus).
3. After successful FFR-guided PCI, no FNL is left.
4. Any remaining lesion with diameter stenosis ≥90% or FFR\<0.8 after PCI.
5. Left main coronary artery lesion.
6. CABG planned by the investigators according to extent and severity of coronary artery disease.
A Case of Sesamoid Displacement Causing the First Metacarpophalangeal Joint Locking

Traumatic sesamoid displacement of the first metacarpophalangeal joint can affect thumb function.

Although occurrence is rare, the mechanism of the displacement is commonly complex and varied. Understanding the mechanism is critical for treatment of the disorder. We herein present a locked thumb MCPJ caused by sesamoid displacement.

Eligibility Criteria:
Inclusion Criteria:

* Traumatic sesamoid displacement

Exclusion Criteria:

* Pathologic sesamoid disorder
STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial

The aim of the study is to test if intracerebral haemorrhage (ICH) patients who have contrast extravasation on computed tomography angiography, the "spot sign", have lower rates of haematoma growth when treated with tranexamic acid within 4.5 hours of stroke onset, compared to placebo.


Eligibility Criteria:
Inclusion Criteria:

* Patients presenting with an acute ICH
* Contrast extravasation within the haemorrhage, "spot sign", evaluated from the CTA according to three criteria, all of which must be present:

  1. Serpiginous or spot-like appearance within the margin of a parenchymal haematoma without connection to an outside vessel;
  2. The density (in Hounsfield units) should be greater than that of the background haematoma (site investigators are not required to document the density); and
  3. No hyperdensity at the corresponding location on non-contrast CT.
* Age ≥18 years
* Treatment can commence within 1 hour of initial CT and within 4.5 hours of symptom onset (or in patients with unknown time of symptom onset, the time patient was last known to be well)
* Informed consent has been received in accordance to local ethics committee requirements

Exclusion Criteria:

* Glasgow coma scale (GCS) total score of \<8
* Brainstem ICH
* ICH volume \>70 ml as measured by the ABC/2 method
* ICH known or suspected by study investigator to be secondary to trauma, aneurysm, vascular malformation, haemorrhagic transformation of ischaemic stroke, cerebral venous thrombosis, thrombolytic therapy, tumor, or infection
* Contrast already administered within 24 hours prior to initial CT or contraindication to imaging with CT contrast agents (e.g. known or suspected iodine allergy or significant renal failure)
* Any history or current evidence suggestive of venous or arterial thrombotic events within the previous 12 months, including clinical, ECG, laboratory, or imaging findings. Clinically silent chance findings of old ischemia are not considered exclusion.
* Hereditary or acquired haemorrhagic diathesis or coagulation factor deficiency.
* Use of heparin, low-molecular weight heparin, GPIIb/IIIa antagonist, or oral anticoagulation (e.g. warfarin, factor Xa inhibitor, thrombin inhibitor) within the previous 14 days, irrespective of laboratory values
* Pregnancy (women of childbearing potential must be tested)
* Planned surgery for ICH within 24 hours
* Concurrent or planned treatment with haemostatic agents (e.g. prothrombin complex concentrate, vitamin K, fresh frozen plasma, or platelet transfusion)
* Participation in any investigational study in the last 30 days
* Known terminal illness or planned withdrawal of care or comfort care measures.
* Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
Genetics of Recurrent Early Onset Major Depression

This study will identify specific genes that may cause a predisposition to depression in some families.

Depression is a serious medical illness that is often difficult to diagnose and treat. Studies on patterns of depression within families suggest that inherited genes may cause a predisposition to the disorder. People with early onset depression often have more relatives with depression than people whose depression does not begin until later in life. It is likely that several interacting genes cause this tendency towards the disorder, rather than one specific gene. This study will serve to identify particular genes that may cause a susceptibility to depression in order to better understand the brain mechanisms involved with severe depression. In turn, this may aid in the development of new treatments for depression.

Participation in this observational study will entail one interview and one blood test. Participants will be interviewed, either in person or by telephone, about their personal and family psychiatric history. The blood sample will be collected at a time and location that is convenient for the participant. Participants may also be asked to invite other family members to participate in the study.

For information on a related study please follow this link:

http://clinicaltrials.gov/show/NCT00005914

Eligibility Criteria:
Inclusion Criteria:

* History of recurrent major depression
* Has a parent or sibling with a history of recurrent major depression
* Depression began before the age of 31

Exclusion Criteria:

* Bipolar I (manic-depressive) disorder
* Schizophrenia
Awake Prone Positioning in Spontaneous Breathing Patients With Acute Hypoxic Respiratory Failure Due to Pneumonia

Prone positioning has shown beneficial effects in intubated patients with severe respiratory failure and positive effects in awake patients with COVID-19 pneumonia. Conclusive evidence for patients with AHRF without COVID-19 is still missing. We hypothesis that awake prone position in patients with AHRF is superior to standard supine/semi-recumbent position in terms of reducing the rate of tracheal intubation and/or all-cause death within 28 days after randomization.

Prone positioning has shown beneficial effects in intubated patients with severe respiratory failure and positive effects in awake patients with COVID-19 pneumonia. Since the pandemic the rate of awake prone positioning has increased and became a standard medical therapy in ICUs worldwide. Conclusive evidence for patients with AHRF without COVID-19 is still missing. We hypothesis that awake prone position in patients with AHRF is superior to standard supine/semi-recumbent position in terms of reducing the rate of tracheal intubation and/or all-cause death within 28 days after randomization. Furthermore, we aim to assess safety and tolerability of awake prone positioning in patients with acute hypoxic respiratory failure due to pneumonia on the ICU.

Eligibility Criteria:
Inclusion Criteria:

* The focus of this trial is to treat patients with respiratory failure. The inclusion criteria are selected accordingly. Patients meeting all of the criteria listed below will be included in the study:

  * Patients in the intensive care unit
  * High possibility of Pneumonia (community-acquired pneumonia or hospital-acquired pneumo-nia) either diagnosed by chest x-ray or computed tomography or clinically diagnosed at least with one of the following signs

    * Appearance of purulent secretions or changes in characteristics (color, odor, quantity, consistency)
    * Cough or dyspnea or tachypnea
    * Evocative auscultation
  * Presence of acute hypoxemic respiratory failure (PaO2/FIO2 ≤ 300 mmHg or SpO2/FiO2 ≤ 315)

Exclusion Criteria:

* Patients are excluded from the study if any of the following criteria are met at screening or before ran-domization, a detailed list is shown in the study manual:

  * Age below 18
  * Pregnant woman
  * Patient is unlikely/unable to awake prone positioning, or to be compliant as indicated by the treating team
  * Prolonged need (≥ 4 days) for HFNO, NIV or CPAP before study inclusion
  * Urgent need for endotracheal intubation
  * Invasive Mechanical Ventilation
  * Shock

    o Defined as need for vasopressor ≥ 0.4 mcg/kg/min to maintain a mean blood pressure of ≥ 65 mmHg or systolic blood pressure ≥ 90 mmHg
  * Participation in another clinical interventional trial in the last 3 months
  * Previous Participation in the PROSA Trial
  * Long-term oxygenation therapy (LTOT) or continuous positive airway pressure (CPAP) therapy before hospital admission
  * Treatment
Correlation of Two Methods for Cough Peak Flow Measurement in Intubated Patients

Cough Peak Flow (CPF) seems to be an efficient tool to assess cough capacity for the intensive care unit (ICU) ventilated patient. CPF can be used in the ventilator weaning process, as reflecting the upper airways protection capacity.

CPF requires disconnection of the patient from the ICU ventilator, supplemental material (handheld spirometer, antibacterial filter) and an excellent synchronization between the specialized caregiver and the patient.

We aimed that CPF with the ventilator built-in flow-meter is correlated with CPF using a handheld flowmeter connected to the endotracheal tube.


Eligibility Criteria:
Inclusion Criteria:

* Age \> 18 years
* Mechanically ventilated patient \> 24 hours
* Weaning ventilator phase (PEEP \< 9 cmH2O and Support \< 15 cm H2O)
* Richmond Agitation Sedation Scale between -1 and +1
* Patient's agreement to participate

Exclusion Criteria:

* Pregnant women
* Bronchospasm
* FiO2 \> 70%
* Thoracic surgery \< 7 days
* Abdominal surgery \< 7 days
* Thoracic injury with rib fracture \< 21 days
* Pneumothorax \< 24 hours
Intervening for Increased Quality of Life Among Older People in Sweden

In the wake of the Covid-19 pandemic, Sweden and other countries have become aware of how life has changed; the world is now a "hybrid world" where many daily activities have moved online. The forced physical isolation has also led to an increase in depression and loneliness, especially among elderly people. Traditional interventions often involve physical contact, and there are valuable lessons to be learned from this situation, where physical isolation is forced, in order to mitigate the consequences both during and after this pandemic.

The overall purpose of this project is to study physical activity as a way to engage in and maintain an active lifestyle and /or increase the quality of life and limit mental health problems for older people and to study how scalability, accessibility, commitment, and adherence can be improved with flexible programs with digital tools. The specific research question is:

Is there a difference between the online exercise program and the onsite exercise program in terms of physical activity, balance, motivation, quality of life and mental health?

The results are expected to give insights into how to increase physical activity using flexible programs with digital options and to maintain quality of life among the elderly. By giving the elderly population different options for being physically active and thereby empowering this group, this project contributes to creating a socially sustainable community in which elderly citizens are included.


Eligibility Criteria:
Inclusion Criteria:

* Understand Swedish

Exclusion Criteria:

-
The Association Between Body Constitution and Meridian Energy in Prediabetes

Traditional Chinese medicine (TCM) theories assert that body constitution and meridian energy are the foundations for disease prevention. However, few studies have incorporated TCM concepts into risk factors. This study aimed to examine the association between body constitution and meridian energy in individuals with prediabetes. We conducted a matched case-control study that included 60 individuals with prediabetes. Finally, the reseachers have found that body constitution may be a risk factor fpr progression to type 2 diabetes mellitus in individuals with prediabetes.

Objective: Traditional Chinese medicine (TCM) theories assert that body constitution and meridian energy are the foundations for disease prevention. However, few studies have incorporated TCM concepts into risk factors. This study aimed to examine the association between body constitution and meridian energy in patients with prediabetes.

Methods: The researchers conducted a matched case-control study from January to December 2019 that included 30 adults with prediabetes and 30 healthy controls, matched for age and sex, recruited from the outpatient clinic and health examination center at a teaching hospital in northern Taiwan. Body constitution was measured using the Body Constitution Questionnaire, which classifies the constitution as yang-deficiency, ying-deficiency, and phlegm-stasis, while meridian energy was measured using an Aetoscan meridian energy device (Aeto Technology Co. Ltd., Taiwan). The associations between body constitution, meridian energy, and prediabetes were examined using binary logistic regression analyses.

Conclusion: Body constitution may be a risk factor for progression to type 2 diabetes mellitus in patients with prediabetes and warrants further study.

Eligibility Criteria:
Inclusion Criteria:

* Previously diagnosed prediabetes with a hemoglobin A1c (HbA1c) of 5.7-6.4% and a f asting plasma glucose (FPG) of 100-125 mg/dL
* Aged ≥20
* provided informed consent
* The controls were healthy individuals whose FPG level was 100 mg/dL in at least two blood tests in the past 6 months.

Exclusion Criteria:

* Use of a hypoglycemic agent within the past 3 months
* Self-reported catastrophic illness in the last 6 months
* Pregnant and/or lactating
* Presence of pacemaker.